Aimee Mcrae-Clark to Treatment Outcome
This is a "connection" page, showing publications Aimee Mcrae-Clark has written about Treatment Outcome.
Connection Strength
0.833
-
The effect of oxytocin, gender, and ovarian hormones on stress reactivity in individuals with cocaine use disorder. Psychopharmacology (Berl). 2020 Jul; 237(7):2031-2042.
Score: 0.077
-
Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug Alcohol Depend. 2018 06 01; 187:270-277.
Score: 0.067
-
Approach bias modification for cannabis use disorder: A proof-of-principle study. J Subst Abuse Treat. 2018 04; 87:16-22.
Score: 0.066
-
Therapeutic Benefit of Smoked Cannabis in Randomized Placebo-Controlled Studies. Pharmacotherapy. 2018 01; 38(1):80-85.
Score: 0.065
-
Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users. Am J Drug Alcohol Abuse. 2018; 44(1):47-55.
Score: 0.064
-
Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Res. 2017 Mar; 249:318-320.
Score: 0.061
-
Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women. Addict Behav. 2016 09; 60:197-202.
Score: 0.058
-
Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict. 2016 Jan; 25(1):69-75.
Score: 0.057
-
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015 Nov 01; 156:29-37.
Score: 0.056
-
Methylphenidate transdermal system in adults with past stimulant misuse: an open-label trial. J Atten Disord. 2011 Oct; 15(7):539-44.
Score: 0.039
-
A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009 Nov 01; 105(1-2):132-8.
Score: 0.037
-
Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict. 2006 Sep-Oct; 15(5):404.
Score: 0.030
-
A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. Am J Addict. 2004 Jan-Feb; 13(1):53-63.
Score: 0.025
-
Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depress Anxiety. 2004; 19(3):190-6.
Score: 0.025
-
Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. Psychol Addict Behav. 2022 Aug; 36(5):505-514.
Score: 0.021
-
Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug Alcohol Depend. 2021 01 01; 218:108383.
Score: 0.020
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.019
-
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.016
-
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug; 169(8):805-12.
Score: 0.011
-
A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on craving in cocaine-dependent individuals. Psychopharmacology (Berl). 2013 Apr; 226(4):739-46.
Score: 0.011
-
Extinction of drug cue reactivity in methamphetamine-dependent individuals. Behav Res Ther. 2010 Sep; 48(9):860-5.
Score: 0.010